CTLA4 and nasopharyngeal carcinoma: The first PD-1/CTLA-4 bi-specific antibody product approved worldwide was developed by Akeso, Inc. The range of this antibody is applicable to a series of solid tumors, such as cervical cancer, lung cancer, gastric cancer, and NPC (163).